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To elucidate the mode of action of norakin agamst mlluenza A virus we sequenced the hemagglutinln gene of 11 no~dktn-rcsIstant mutants Resrst- 
ante was coupled wtth 1-3 ammo acrd exchanges The majority of mutattons was localized m the HA2 polypepttde and was mostly associated 
with changes m charge or polarity of the ammo acids. The ammo actd substttutrons are discussed m the context of the 3D structure of X31 hemagglu- 
tmm considered to be representative of the mfluenza hemagglutmms Most of the mutations appear to destabiltze the pH 7 0 structure by dtstortmg 
or destroying hydrogen bonds as well as salt-bridges which are responstble for mtra- and mtersubumt contacts, whtle others destabthze the location 
of the fusion pepttde, facihtating conformational changes m the presence of the Inhibitor. 
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1. INTRODUCTION 
There is a need for effective antiviral agents to pre- 
vent and to treat influenza and other respiratory infec- 
tions. The anticholinergi~ anti-Parkinson drug, 
norakin, was described to inhibit the multiplication of 
different ortho- and paramyxoviruses like influenza A 
and B, measles [1,2] and RS virus [3]. 
For influenza A the major envelope glycoprotein 
hemagglutinin was identified as the target of norakin 
action [4]. As shown earlier, norakin inhibits the entry 
of influenza A virus into the cell [5] as well as virus- 
induced hemolysis and the conformational change of 
viral hemaggiutinin at acidic PI-L [4]. 
To elucidate the mode of action of norakin, a series 
of norakin-resistant mutants of the highly norakin- 
sensitive strain A/FPV/Weybridge was isolated [2,6], 
and their hemagglutinin genes were sequenced. After 
sequencing the first 4 mutants it became clear that 
resistance to norakin is not determined by a distinct 
{single) mutation [6]. Amino acid substitutions can take 
place at different positions along the whole 
polypeptide. 
Here we describe data of amino acid substitutions in 
the hemagglutinin of a further 7 norakin-resistant 
mutants. On the basis of the 3D structure of the hemag- 
glutinin of strain X31 [7], the locations and possible 
consequences of the mutations were analysed. 
Ionic charge-charge interactions were counted m an all-or-none 
fashion, depending on whether the interacting groups of atoms were 
within a cutoff distance of 4 A or not. Hydrogen bond interactions 
were treated similarly. The cutoff distance between the H-bond 
donor and acceptor was 2.8 A. 
Correspondence address: S. Prosch, Instttute of Virology, Charite, The accessibility of each atom is defined according to Richards 
Schumannstr. 20121, Berlin 1040, GDR 1131. The computer program to calculate the accessible surface area 
2. MATERIALS AND METHODS 
2 1. Virus infectron 
Influenza A/FPV/Weybridge was kmdly provided by Dr Y. Ghen- 
don (Research institute for Viral Preparations, Moscow, USSR). The 
norakin-resistant mutants were isolated following 3 plaque purifica- 
tions on primary chrck embryo cells (CEC) in the presence of 20 pg 
norakm per ml as described previously [2]. All strains were grown in 
the allantoic cavity of 1 i-day-old embryonated eggs. Virus ttters and 
norakin sensitivittes were determmed by plaque tests on CEC. 
2.2. Virus RNA isolatron 
The viruses were purifted by repeated centrtfugatton on sucrose 
density gradients. Total viral RNA was isolated by the method of 
Hay et al. [8] and stored at -20°C. 
2.3. ~ucleotlde sequence analysis 
The hemagglutinin genes were sequenced using the dideox- 
ynucleotide chain termination procedure of Sanger et al. [9] and Air 
[IO] with minor modifications. The primers were complementary to 
nucleotides 5-20, 228-243, 426-438, 571-586, 831-846, 990-1005, 
1112-1127, 1314-1329 and 1525-1540 according to the gene 4 se- 
quence of A/FPV/Weybridge as determined by Hay et al (personal 
commumcation). 
2.4. Computer anal.vsts 
Amino acid sequences were aligned accordmg to Lipman and Pear- 
son [1 11 with a gap penalty of 0.5. The total homology between the 
HAS of strain X31 [ 121 and stram Weybridge (Prosch et al., un- 
published) was 41% for HAl and 66% for HA2, respecttvely. Due 
to the high degree of homology, there is little doubt about the 
similarity of the 3D structures of X31 and Weybridge HA. 
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Table I 
July 1990 
Charactertratton of amino acid substitutrons in the hemagglutmm 
Change due to mutation Mutant Position”.b in subunh Accessibihty Type of 
of stde secondarv 
HAI HA2 chatn in %d structure’ Iomc 
- 
2 
15’ 
10 
12’ 
7 
4 
5‘ 
1’ 
6 
205 G-R 
205 G-R 
122 T-P 
91 RkY 
210 H-N 
112 D4Ci 
112 D--I 
131 E-K 
134 G---rD 
3 
3 
114 E-D 
41 T--A 
25 
2’ 
2’ 
8 
74 
8 
61 
16 
36 A-S 
50 G-V 
107 T-A 
19 D-N 
3 280 E-D 
3 
2.5 
0 
60 
52 
5 
32 
+O 
_ -0 
-+ 
0-- 
o- + 
o-+ 
_-_ 
o-o 
o-o 
+ --0 
+-0 
Ok0 
o-o 
o-o 
p-0 
_-_ 
o-o 
+-0 
83 W’-C 
123 R-S 
Hydro- 
phobtcuy’ 
~ 1.771 0 
- 1 77- 2.44 
- I .566- 2.26 ~ 
0 - ~ 1 .I7 
0 b-263 
0 - - 2.64 
~ 1.64~ ~ 1.77 
0.214 1.73 
0 211 0.40 
~ 2.64- 2.24 
- 1.7- -0.28 
0.40- -0.27 
0 - 1.46 
0.21- 0 40 
~ 1.77- 0.28 - 
~ 1.46+ 1.77 - 
2.55- 0.90 
~ 2.641 0.27 - 
Sec. structure 
probabthtyP 
1 Ol--0.57 
1 01-0.69 
1.19---*0.74 
0.75-0.93 
0.75-0.93 
1.51-1.01 
1.19-0.5s 
0.83 - I .32 
0.87-0.89 
1 42-0.77 
0 57-1.06 
0.83-I 42 
1.46-1.56 
1.08--‘0.70 
0.7740 98 
Volume 
(A’)” 
74, 44 
74-124 
90- 108 
44---t 74 
44-112 
44-112 
90- 74 
77- 81 
771 61 
112-124 
99- 78 
61- 61 
431 91 
77- 61 
741 78 
90--t 74 
144--, 12 
11’1 61 
’ Positton of the amino acids according to X31 numbertng 
’ Smgle letter code 
’ Results pubhshed previously [6] 
d The mean accessibdny of the whole HA protem IS 24% of the maximal accessibility [14] 
’ Accordmg to Dictionary of Secondary Structure of Proteins (DSSP) [15] 
f Scale according to the competition in charged amino acid side chains [16] 
* Change of the secondary structure probabihty of the type observed in X31 [ 171 
’ Molar volume of the restdue [I81 
I Accessibihty of the total residue 
Mutan! 2 and 15: 
Remurks: Probable srructural consequences of the urnmo ucld subrrliutrom 
Asp 112 of HA2 forms four hydrogen bonds to residues 1 and 3-6 of the N-terminal tfuston) peptide of HA2. Substitution of Asp by Gly 
or Tyr should destroy this interaction and thereby increase the mobtlity of the N-terminus, as well as destabihze the position of the fusion pepttde 
in the pH 7.0 conformation. 
Mutant 10: 
Glu-131 of HA2 is buried in the HA2-HA2 interface, forming a hydrogen-bonded salt lurk as well as hydrogen bonds to Arg-163 and to Arg-127 
of the same chain. Substitutton of Glu-131 by the posittve charged Lys should eliminate these interacttons and weaken trimer stabtlity. 
Mutant 7 and 4: 
Substitution of the small uncharged City-205 by the posttive charged Arg should reduce the high mobtlity of the polypepttde cham in this region 
and possibly result m drastic conformattonal change 
Glu-114 forms a salt bridge to Lys-117 m that part of the long helix of the same HA2 polypepttde which stabihzes the location of the fusion 
peptide of a second HA2 chain via a hydrogen bond. When exchanged for Asp, which is smaller by one C-atom, the H-bond might not be formed, 
resulting in a destabtlization of the fusion pepttde in the pH 7.0 conformation. 
Mutant 5: 
The substitution of Thr-122 by Pro may restrtct the high flextbihty of thts region in the polypeptide chain. 
Thr-41 of HA2 hes m the HA2-HA2 interface and forms hydrogen-bond to Thr-21 and Asp-37 of a second HA2 molecule which should be 
absent when Thr-41 is substituted by Ala. 
Mulunl I: 
In the HA1 of strain X31 position 91 is occupied by Ser which forms a hydrogen bond to Asp-271 of the same polypeptide chain. The Arg-91 
in strain Weybrtdge may engage in a salt brtdge to Asp-271. This should be destroyed by replacement of Arg by Tyr. 
His-210 is buried in the interface between two HA1 polypepttdes. It forms a salt bridge to Asp-101 and a hydrogen bond to Arg-220 of another 
HAI molecule. Both mteracttons may be destroyed or at least weakened by the mutation to Asn. 
Mutant 6’ 
Ala-36 of HA2 forms an intramolecular hydrogen bond with Asp-19 of the same HA2 polypeptide chain. Substitution by Ser should destroy 
this hydrogen bond, probably destabihzmg the pH 7.0 conformation 
Mutant 16: 
Asp-19 IS localized on the surface of the protein. The exchange for Asn would Increase the net charge on the surface. (The hydrogen bond 
to Ala-36 (see above) would be preserved.) 
Muranr 3: 
Like Tyr-83 in stram X31, Trp-83 may be buried in the Interface between two HA2 molecules and Juxtaposed to Arg-85 of another subunit. 
Substitutton by the smaller Cys would destroy any posstble Interaction in this contact region. 
Arg-123 of HA2 interacts with Glu-120 of the same polypeptide cham via a hydrogen bond and a hydrogen-bonded salt link. These would be 
20 destroyed by the substitution, and the decrease of electrostattc charge should further destabthze mtramolecular connecttons. 
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IS described m detail m Baumann et al. [14]. The reference state for 
accessibility (To) for amino acid X is taken from the extended confor- 
mation of the ohgopeptide: Gly-Gly-X-Gly-Gly. 
3. RESULTS AND DISCUSSION 
Norakin-resistant mutants contained one (S), two (5) 
or three (1) mutations in their hemagglutinin gene 
resulting in amino acid substitutions (Table I). The sites 
are distinct and distributed over the polypeptide chains 
of both subunits, being scattered in space throughout 
the structure of the oligomer. The majority of amino 
acid substitutions (12 from 18) were in the HA2 
polypeptide (Table I, column 2). Nine of 11 mutants 
show at least one amino acid exchange resulting in a 
change of charge; however, not in a fixed direction 
(Table I, column 5). Amino acid substitutions in the 
hemagglutinins of mutants 5 and 6 involve a change of 
polarity. 
Furthermore, not only the polarity or hydrophobici- 
ty is significantly altered by most mutations (Table I, 
column 6) but also the residue volume (Table I, column 
8) and the propensity of each amino acid residue to 
stabilize the local secondary structure (Table I, columns 
4 and 7). We observed several mutations which would 
tend to disrupt strong intra- and intermolecular interac- 
tions like salt bridges and H-bonds (Table I, remarks). 
Compared with the mean accessibility (24%) of HA 
amino acid residues, at least one substituted amino acid 
residue of each mutant (with the exception of mutant 
12) exhibits a very low accessibility (O-8%) (Table I, 
column 3). This is remarkable in view of the generally 
higher frequency of mutations at the protein surface. 
Interestingly, all nonaccessible side chains discussed 
here are parts of secondary structure elements (Table I, 
column 4), forming the interface between elements of 
the HA. 
Thus, the secondary structure type should be con- 
served, but as a result of the mutations the stabili- 
ty/flexibility of the secondary structure elements may 
be altered, permitting distinct movements of such 
elements with respect to each other. 
How do these mutations relate to the mode of action 
of norakin as an inhibitor of influenza virus penetra- 
tion? They should allow the acid-dependent conforma- 
tional change of the hemagglutinin - the prerequisite of 
fusion between viral and endosomal membranes [ 191 -
in the presence of the inhibitor. 
Some of the sites (91, 112, 114) where amino acid 
substitutions to norakin-resistance occur were also 
found by Daniels et al. [20] in mutants resistant o high 
amantadine concentrations. However, with the excep- 
tion of the amantadine-resistant mutant 4Y and the 
norakin-resistant mutant 2, the individual amino acid 
exchanges are not identical and the degree of cross- 
resistance varies greatly between individual mutants [2] 
(Schroeder et al., in preparation). Whether these dif- 
ferences in molecular mode of action of norakin on the 
one side and high amantadine concentrations on the 
other are caused by indirect (e.g. pH) or direct drug ef- 
fects on the target protein is currently under in- 
vestigation. 
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the All Union Institute of Molecular Biology, Kolzovo, USSR pro- 
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